COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,955 Articles (22,604 medRxiv, 8,351 bioRxiv)

Most recent first Previous |  Page 340: Articles 3391-3400  | Next

What Risk Factors to Cause Long COVID and Its Impact on Patient Survival Outcomes when Combined with the Effect from Organ Transplantation in the Acute COVID
Dong, J., Nyandemoh, A. N., Anzalone, J., Dai, H., Mannon, R.
10.1101/2023.08.03.23293622 — Posted: 2023-08-08
Prediction of Daily New COVID-19 Cases - Difficulties and Possible Solutions
Liu, X.
10.1101/2023.08.04.23293429 — Posted: 2023-08-08
Four Models of Wastewater-Based Surveillance for SARS-CoV-2 in Jail Settings: How Monitoring Wastewater Complements Individual Screening
Kennedy, S. S., Spaulding, A. C., SWANSS Writing Group
10.1101/2023.08.04.23293152 — Posted: 2023-08-08
Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model
Mundo Ortiz, A. I., Nasri, B.
10.1101/2023.08.04.23293662 — Posted: 2023-08-08
Genetic Variant rs1205 is Associated with COVID-19 Outcomes: The Strong Heart Study and Strong Heart Family Study.
Best, L. G., Erdei, E., Haack, K., Kent, J. W., Malloy, K., Newman, D. E., O'Leary, M., O'Leary, R., Sun, Q., Navas-Acien, A., Franceschini, N., Cole, S. A.
10.1101/2023.08.04.23293551 — Posted: 2023-08-08
Infant and Neonatal Mortality During the Covid-19 Pandemic: An Interrupted Time Series Analysis From Five Low- and Middle-Income Countries
Wagner, Z., Heft-Neal, S., Wang, Z., Jing, R., Bendavid, E.
10.1101/2023.08.03.23293619 — Posted: 2023-08-08
NVX-CoV2373 ancestral and NVX-CoV2540 BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
Bricker, T. L., Joshi, A., Soudani, N., Scheaffer, S., Patel, N., Xabier, M. G., Smith, G., Diamond, M., Boon, A. C.
10.1101/2023.08.07.552330 — Posted: 2023-08-08
Within-host evolution of SARS-CoV-2: how often are mutations transmitted?
Korosec, C. S., Wahl, L. M., Heffernan, J. M.
10.1101/2023.08.08.552503 — Posted: 2023-08-08
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5
Kaku, Y., Kosugi, Y., Uriu, K., Ito, J., Kuramochi, J., Sadamasu, K., Yoshimura, K., Asakura, H., Nagashima, M., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Sato, K.
10.1101/2023.08.08.552415 — Posted: 2023-08-08
Determinants of COVID-19 booster uptake in the Netherlands, Autumn 2022: how well were those at risk for severe disease reached?
van Roekel, C., Labuschagne, L., Pijpers, J., van Roon, A., Smagge, B., Ferreira, J. A., Hahne, S., de Melker, H.
10.1101/2023.08.04.23293632 — Posted: 2023-08-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).